Anxiety disorders-including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, and specific phobia-affect more than 87 million people in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). These diseases can be chronic or episodic, but all have a serious impact on patients' quality of life. Decision Resources, Inc., announces a new study, Anxiety Disorders, that evaluates the opportunities awaiting new drugs in this marketplace.


In all major markets, increasing public awareness will broaden acceptance of anxiety disorders as treatable diseases. This awareness, coupled with improvements in the ability of general practitioners to recognize and distinguish between these disorders, will spur an estimated 10% increase in diagnosis by 2009. Anxiety Disorders explores how an increase in the diagnosed population will expand the anxiety market from $2 billion in 1999 to almost $3 billion in 2009. This study also explains the following:

  -- Why selective serotonin reuptake inhibitors/serotonin norepinephrine      reuptake inhibitors (SSRIs/SRNIs) are the clear market winners, despite      the lower cost of benzodiazepines.   -- How general practitioners' growing awareness of anxiety disorders and      comfort level with prescribing new drugs will affect the anxiety      disorder market.   -- The promise of neuropeptide antagonists as a significant improvement      over the existing SSRI/SNRI class, and why these drugs are in a      position to garner $1.5 billion in their peak year of sales for anxiety      disorders.  

Anxiety Disorders offers invaluable market intelligence for pharmaceutical companies competing in the affective disorders market, and is a part of Cognos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, 781-296-2553,

Decision Resources to Publish Genomics and Drug Development: Impacts and Strategic Implications

View Now